A single-dose live-attenuated YF17D-vectored SARS-CoV-2 vaccine candidate
Loading...
Date
2021
Journal Title
Journal ISSN
Volume Title
Publisher
nature
Abstract
The expanding pandemic of coronavirus disease 2019 (COVID-19) requires the
development of safe, efcacious and fast-acting vaccines. Several vaccine platforms
are being leveraged for a rapid emergency response1
Here we describe the
development of a candidate vaccine (YF-S0) for severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2) that uses live-attenuated yellow fever 17D (YF17D)
vaccine as a vector to express a noncleavable prefusion form of the SARS-CoV-2 spike
antigen. We assess vaccine safety, immunogenicity and efcacy in several animal
models. YF-S0 has an excellent safety profle and induces high levels of SARS-CoV-2
neutralizing antibodies in hamsters (Mesocricetus auratus), mice (Mus musculus) and
cynomolgus macaques (Macaca fascicularis), and—concomitantly—protective
immunity against yellow fever virus. Humoral immunity is complemented by a
cellular immune response with favourable T helper 1 polarization, as profled in mice.
In a hamster model2
and in macaques, YF-S0 prevents infection with SARS-CoV-2.
Moreover, a single dose conferred protection from lung disease in most of the
vaccinated hamsters within as little as 10 days. Taken together, the quality of the
immune responses triggered and the rapid kinetics by which protective immunity
can be attained after a single dose warrant further development of this potent
SARS-CoV-2 vaccine candidate.
Description
Research Article